Estamos no ar no ! Saiba mais

Vera Therapeutics

VERA

Valor de mercado US$ 2,01 bi

27,88 USD

-0,69

2,42%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

27,50

-0,38

1,36%

1 dia

-2,42%

5 dias

-4,23%

1 mês

-12,24%

3 meses

-28,73%

6 meses

-34%

No acumulado do ano

-42,66%

1 ano

-8,62%

5 anos

70,94%

10 anos

142,43%

Sobre: Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Funcionários: 361

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 16,7%

Neutro 66,7%

Negativo 16,7%

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 16,700 shares of Class A common stock and restricted stock units (RSUs) underlying 8,350 shares of Class A common stock to five (5) new employees under the Inducement Plan.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

What's Going on With Vera Therapeutics Stock on Tuesday?

Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility after the company announced data from the ORIGIN 3 trial.

What's Going on With Vera Therapeutics Stock on Tuesday?

Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.

Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results

Why is Vera Therapeutics stock reversing its premarket gains?

Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (atacicept-vymj) met all primary and secondary endpoints in the final 104-week efficacy analysis of its Phase 3 ORIGIN 3 trial for primary IgA nephropathy (IgAN).

Why is Vera Therapeutics stock reversing its premarket gains?

Schaeffers Research

Vera Stock Slides Despite Positive Phase 3 Results

Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after disclosing positive late-stage ORIGIN 3 trial results for the company's TRUTAKNA drug.

Vera Stock Slides Despite Positive Phase 3 Results

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR, Prevented IgAN Disease Progression Through 2 Years in ORIGIN 3 Final Analysis

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.

Vera Therapeutics to Participate at Upcoming Investor Conferences

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™